Ropeginterferon alfa-2b

Blood Cancer: AOP Health Announces New Findings in Patients With Polycythemia Vera Published in Medical Journal Leukemia

Retrieved on: 
Tuesday, September 19, 2023
Science, Research, Pharmaceutical, Finance, Oncology, General Health, Health, Professional Services, BAT, Civil service commission, Polycythemia vera, European Hematology Association, Hydroxycarbamide, Medical school, Multimedia, Ropeginterferon alfa-2b, H, Patient, Titan IIIB, AOP, Annual general meeting, Medical University of Vienna, Paper, ATC, Polycythemia, Leukemia, European Commission, Safety, Disease, Pharmaceutical industry, PV

AOP Orphan Pharmaceuticals GmbH (AOP Health) announced the publication of final results on the recently developed interferon therapy, ropeginterferon alfa-2b, in patients with polycythemia vera (PV) in the prestigious journal Leukemia1.

Key Points: 
  • AOP Orphan Pharmaceuticals GmbH (AOP Health) announced the publication of final results on the recently developed interferon therapy, ropeginterferon alfa-2b, in patients with polycythemia vera (PV) in the prestigious journal Leukemia1.
  • The full publication expands on results presented at the Annual Meeting of the European Hematology Association.
  • Results of long-term treatment in the CONTINUATION-PV study provide further evidence of the disease modifying capacity of ropeginterferon alfa-2b in PV.
  • Event-free survival in patients with polycythemia vera treated with ropeginterferon alfa-2b versus best available treatment.

Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology

Retrieved on: 
Wednesday, August 30, 2023
GSK plc, Disease, Headache, Essential thrombocythemia, Bleeding, Prevalence, Conditional sentence, Hydroxycarbamide, Bone marrow, Genetic testing, Platelet, Petechia, Aspirin, Common, LAS, Bruise, Dizziness, Spleen, Novartis, Patient, Risk, Physiology, Plateletpheresis, Blood, MMB, CTI, Thrombocythemia, United Kingdom, Abdomen, Diagnosis, Oncology, Haematopoietic system, Skin, Medical device, Medical imaging, Pacritinib, Momelotinib, Ropeginterferon alfa-2b

LAS VEGAS, Aug. 30, 2023 /PRNewswire/ -- DelveInsight's Essential Thrombocythemia Market Insights report includes a comprehensive understanding of current treatment practices, essential thrombocythemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • These factors along with the expected launch of emerging therapies will boost the essential thrombocythemia market in the forecasted period.
  • As per DelveInsight analysts, total prevalent population of essential thrombocythemia in the 7MM was 240K in 2020.
  • Estimates observed that the age-group 60-80 years accounted for highest cases of essential thrombocythemia in the United States.
  • To know more about essential thrombocythemia treatment, visit @ Essential Thrombocythemia Treatment Drugs

Essential Thrombocythemia Market to Witness Upsurge in Growth by 2032, Predicts DelveInsight | Key Companies to Look Out - Imago BioSciences, Incyte, Karyopharm, Novartis, PharmaEssentia, Celgene, Kartos, Sierra Oncology

Retrieved on: 
Wednesday, August 30, 2023
GSK plc, Disease, Headache, Essential thrombocythemia, Bleeding, Prevalence, Conditional sentence, Hydroxycarbamide, Bone marrow, Genetic testing, Platelet, Petechia, Aspirin, Common, LAS, Bruise, Dizziness, Spleen, Novartis, Patient, Risk, Physiology, Plateletpheresis, Blood, MMB, CTI, Thrombocythemia, United Kingdom, Abdomen, Diagnosis, Oncology, Haematopoietic system, Skin, Medical device, Medical imaging, Pacritinib, Momelotinib, Ropeginterferon alfa-2b

LAS VEGAS, Aug. 30, 2023 /PRNewswire/ -- DelveInsight's Essential Thrombocythemia Market Insights report includes a comprehensive understanding of current treatment practices, essential thrombocythemia emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Points: 
  • These factors along with the expected launch of emerging therapies will boost the essential thrombocythemia market in the forecasted period.
  • As per DelveInsight analysts, total prevalent population of essential thrombocythemia in the 7MM was 240K in 2020.
  • Estimates observed that the age-group 60-80 years accounted for highest cases of essential thrombocythemia in the United States.
  • To know more about essential thrombocythemia treatment, visit @ Essential Thrombocythemia Treatment Drugs

New Study Demonstrates Ropeginterferon Alfa-2b-njft Is a Cost-Effective Treatment Option for a Broad Range of Patients with Polycythemia Vera

Retrieved on: 
Friday, August 4, 2023
Oncology, Health, Other Health, Research, Science, Pharmaceutical, Biotechnology, HU, Ruxolitinib, Medical Affairs Bureau, Senior, Hydroxycarbamide, Life imprisonment, Ropeginterferon alfa-2b, Case Comprehensive Cancer Center, Quality of life, National Comprehensive Cancer Network, Quality-adjusted life year, Journal of Comparative Effectiveness Research, Polycythemia vera, PV, MS, NCCN, QALY, Journal, Peginterferon alfa-2a, Journal of the National Comprehensive Cancer Network, Polycythemia, Patient, HIV disease progression rates, Risk, Phlebotomy, Treatment, Hematology, Mortality, TES, Myeloproliferative neoplasm, Safety, News, MPN, Pharmaceutical industry, MD

The analysis, titled “Cost-Effectiveness of Ropeginterferon Alfa-2b-njft for the Treatment of Polycythemia Vera,” showed that ropeginterferon alfa-2b-njft provided a cost-effective benefit for a broad range of patients with polycythemia vera (PV) versus first-line hydroxyurea followed by ruxolitinib.

Key Points: 
  • The analysis, titled “Cost-Effectiveness of Ropeginterferon Alfa-2b-njft for the Treatment of Polycythemia Vera,” showed that ropeginterferon alfa-2b-njft provided a cost-effective benefit for a broad range of patients with polycythemia vera (PV) versus first-line hydroxyurea followed by ruxolitinib.
  • Cost effectiveness was demonstrated in a modeled population including both low- and high-risk patients receiving first- or second-line treatment with ropeginterferon alfa-2b-njft.
  • Findings from the study conclude ropeginterferon alfa-2b-njft is a cost-effective treatment option for a broad range of patients with PV, including both low- and high-risk patients and patients with and without prior cytoreductive treatment with hydroxyurea.
  • “Ropeginterferon alfa-2b-njft has demonstrated safety and efficacy in studies including both low- and high-risk patients and patients with and without prior cytoreductive treatment with HU.

New ropeginterferon alfa-2b Data Suggest Alternate Dosing Schedule May Achieve Greater and Quicker Complete Hematologic and Molecular Responses in Polycythemia Vera

Retrieved on: 
Friday, June 30, 2023
Oncology, Health, Clinical Trials, General Health, Pharmaceutical, Biotechnology, CHR, Ruxolitinib, Experimental Hematology, Polycythemia vera, Hydroxycarbamide, Ropeginterferon alfa-2b, Aes, PV, Trial of the century, HIV disease progression rates, Patient, Risk, ALT, Myeloproliferative neoplasm, Polycythemia, AST, MPN, Pharmaceutical industry

This study, which was conducted in China, demonstrated the efficacy and tolerability of ropeginterferon alfa-2b using an alternate dosing regimen that has a higher starting dose and a more rapid dose titration as compared to current U.S. label dosing.

Key Points: 
  • This study, which was conducted in China, demonstrated the efficacy and tolerability of ropeginterferon alfa-2b using an alternate dosing regimen that has a higher starting dose and a more rapid dose titration as compared to current U.S. label dosing.
  • The publication, titled “A new dosing regimen of ropeginterferon alfa-2b is highly effective and tolerable: findings from a phase 2 study in Chinese patients with polycythemia vera,” was published in Experimental Hematology & Oncology and co-authored by PharmaEssentia researchers.
  • PV is the most common myeloproliferative neoplasm (MPN) and a long-term, potentially life-threatening disease with limited approved treatment options.
  • Long-term treatment and follow-up of the patients in the study are planned to assess progression-free and overall survival.

AOP Health: Completed Study Strengthens Clinical Development Program for ropeginterferon alpha 2b (Besremi®) in polycythaemia vera

Retrieved on: 
Friday, June 2, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Chronic pain, Drug development, The New England Journal of Medicine, Ropeginterferon alfa-2b, Bone marrow, Multimedia, Patient, AOP, Rare, Safety, Fondazione Child, Pharmaceutical industry, PV

With these clinical studies, including PEGINVERA, PROUD-PV , and CONTINUATION-PV , AOP Health opened a new area of treatment options for patients suffering from PV.

Key Points: 
  • With these clinical studies, including PEGINVERA, PROUD-PV , and CONTINUATION-PV , AOP Health opened a new area of treatment options for patients suffering from PV.
  • AOP Health’s comprehensive development program in PV is considered by many key opinion leaders as the most significant development in the field of PV treatment in the past 30 years.
  • A post-approval safety study (BESREMI-PASS) with a recruitment period of about three years has just completed patient recruitment.
  • “The global marketing authorizations of BESREMi®, all based on AOP Health´s clinical development program conducted in Europe, are proof of the integrated drug development and commercialization expertise of AOP Health.

PharmaEssentia Initiates Phase 3b Trial of Ropeginterferon alfa-2b-njft Investigatng New Dosing Regimen for Patients With Polycythemia Vera (PV)

Retrieved on: 
Wednesday, May 3, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Clinical Trials, Other Health, CHR, Ruxolitinib, ECLIPSE, Polycythemia vera, Icahn School of Medicine at Mount Sinai, Stroke, Bone marrow, Mutation, Medicine, Mount Sinai, Ropeginterferon alfa-2b, Stem cell, PV, Malignancy, Patient, Risk, Hematology, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Food, Disease, Pharmaceutical industry

The primary endpoint is the proportion of patients achieving a CHR, defined as hematocrit

Key Points: 
  • The primary endpoint is the proportion of patients achieving a CHR, defined as hematocrit
  • There is a 48-week study period followed by a 28-day safety follow-up.
  • Those who respond to treatment will be eligible to participate in a long-term extension phase of the study.
  • Topline data from the trial are expected by 2024.

Clinical Review of ropeginterferon alfa-2b Suggests Amended Dosing Schedule May Support Improved Clinical Outcomes in Polycythemia Vera

Retrieved on: 
Thursday, February 2, 2023
Biotechnology, Pharmaceutical, Health, Clinical Trials, Bleeding, Physician, Frontiers, Week, Aes, Ropeginterferon alfa-2b, Hydroxycarbamide, Safety, ECLIPSE, Pancreatic serous cystadenoma, Patient, HIV disease progression rates, News, CHR, Polycythemia, Myeloproliferative neoplasm, Senior, Research, Thrombosis, Risk, Medical Affairs Bureau, MPN, CUP, Hematology, PV, Pharmaceutical industry, Nursing, PMF, Oncology

The research indicates that an amended dosing schedule, with higher initial dose and faster dose titration of ropeginterferon alfa-2b (marketed as BESREMi®), may correlate to earlier complete hematological response (CHR) in polycythemia vera (PV) in adults.

Key Points: 
  • The research indicates that an amended dosing schedule, with higher initial dose and faster dose titration of ropeginterferon alfa-2b (marketed as BESREMi®), may correlate to earlier complete hematological response (CHR) in polycythemia vera (PV) in adults.
  • The analysis titled, “An alternative dosing strategy for ropeginterferon alfa-2b may help improve outcomes in myeloproliferative neoplasms: An overview of previous and ongoing studies with perspectives on the future,” was co-authored by PharmaEssentia researchers.
  • Data from an investigator-initiated trial in Korea (n=45; hydroxyurea naïve or pre-treated PV patients) indicated higher hematologic and molecular responses at 6 months.
  • Several planned or ongoing Phase 3 clinical trials will further evaluate this regimen of ropeginterferon alfa-2b in ET (SURPASS and EXCEED trials) and PV (ECLIPSE trial).

AOP Health presents latest updates on BESREMi® (Ropeginterferon alfa-2b) in Polycythaemia Vera at the American Society of Hematology (ASH) 2022 Annual Meeting

Retrieved on: 
Tuesday, December 13, 2022
Biotechnology, Pharmaceutical, Health, Clinical Trials, Titan IIIB, BAT, AOP, Union, Royal commission, MPN, Patient, EMA, Research, Critical care, Phlebotomy, PV, Hydroxycarbamide, Drug development, Health, European Commission, Multimedia, Safety, ELN, ATC, ASH, Polycythemia, Renewable energy, Pharmaceutical industry, Bookkeeping, Ropeginterferon alfa-2b

AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Healths CONTINUATION-PV study ( Reference Kiladjian et al.

Key Points: 
  • AOP Health announced its latest updates on Ropeginterferon alfa-2b in patients with Polycythaemia Vera (PV) from AOP Healths CONTINUATION-PV study ( Reference Kiladjian et al.
  • ASH 2022 ) and the LOW-PV trial, which is an independent investigator-initiated trial supported by AOP Health ( Reference Barbui et al.
  • ASH 2022 ) presented at ASH 2022 Annual Meeting, New Orleans, USA.
  • With this development program AOP Health obtained the first marketing authorization ever of BESREMi for the treatment of Polycythaemia Vera by the European Commission (2019), followed by Switzerland, Liechtenstein and Israel.

AOP Health Presents Final Results From Its CONTINUATION-PV Study - up to 7.5 Years Treatment With BESREMi® (Ropeginterferon alfa-2b) of Polycythaemia Vera Patients - at EHA 2022 Annual Meeting

Retrieved on: 
Monday, June 20, 2022
Health, Stem Cells, Pharmaceutical, Clinical Trials, Oncology, AOP, EHA, Hematocrit, Hydroxycarbamide, US, Thrombosis, Medical school, Survival, Bone marrow, Disease, Titan IIIB, Quality of life, Health, Death, Ruxolitinib, Group, PV, Solution, Embolism, Interferon, Phlebotomy, BAT, Commonwealth, JAK2, Chronic myelogenous leukemia, European Commission, Product, Royal commission, Commonwealth of Independent States, Critical care, HIV disease progression rates, Leukemia, CIS, Patient, Annual general meeting, Risk, Myeloproliferative neoplasm, Safety, European Hematology Association, Medical University of Vienna, Cancer, Research, CML, ATC, Life, EMA, Goal, Renewable energy, Pharmaceutical industry, Medical device, Ropeginterferon alfa-2b

AOP Health has been conducting a pivotal clinical development program, including the studies PEGINVERA, PROUD-PV and CONTINUATION-PV .

Key Points: 
  • AOP Health has been conducting a pivotal clinical development program, including the studies PEGINVERA, PROUD-PV and CONTINUATION-PV .
  • The results of CONTI-PV after 7.5 years of treatment provide further evidence of the value of BESREMi for patients suffering from PV.
  • 1 Ropeginterferon alpha-2b achieves patient-specific treatment goals in Polycythaemia Vera: final results from the PROUD-PV/CONTINUATION-PV studies.
  • The AOP Health Group incorporates several companies including AOP Orphan Pharmaceuticals GmbH with its seat in Vienna, Austria (AOP Health).